In 1990, the American College of Rheumatology marked a turning point: Standardized tender point criteria were proposed for the first time – an attempt to give shape to the invisible pain predominantly experienced by women. However, despite these milestones, the path to diagnosis remained long for many. Why? Because fibromyalgia does not fit into a single lab result but instead creates a multifaceted pattern of pain, fatigue, sleep disturbances, and cognitive impairments – a pattern that both doctors and patients must continue to learn to recognize more sharply to this day ^[1].

Fibromyalgia is a chronic pain syndrome characterized by generalized pain, often accompanied by sleep disturbances, fatigue, mood swings, and “fibro fog” – a cognitive impairmentconcentration and memory problems. The cause is multifactorial: Evidence points to central sensitizationenhanced pain processing in the nervous system, neuroinflammationinflammatory activation of nerve cells/glia, autonomic dysbalanceshifted balance of sympathetic/parasympathetic nervous system, as well as genetic and epigenetic influences [Ref41097025; Ref41821986]. Diagnosis remains clinical: Physicians use established criteria (2010/2011, updated in 2016), assess pain distribution and symptom burden, and exclude other causes – imaging and lab tests serve differential diagnosis, not proof [Ref41097025; Ref39941626]. This is precisely where delays arise: Symptoms are nonspecific, the manifestation varies greatly, and objective biomarkers are still lacking [Ref39941626; Ref41751339].

Untreated, fibromyalgia steals energy, sleep quality, and performance – with consequences for work, training, and quality of life. Studies show a global prevalence of 2–8% with a significant female dominance and high burden on quality of life and healthcare costs ^[1]. Pain hypersensitivity and non-restorative sleep mutually reinforce each other; mood and cognition suffer, particularly affecting high performers. Compounding this are barriers to care: When patients only hint at their concerns during consultations and do not express them clearly, needs remain unrecognized, and therapy gets delayed ^[2]. A lack of understanding of the disease also hinders effective self-management – many desire more precise information on causes, flare management, and treatment options ^[3]. Nutrition also plays a role: A pro-inflammatory pattern correlates with lower pressure pain thresholds, indicating greater pain sensitivity ^[4]; plant-based dietary patterns tend to alleviate musculoskeletal pain ^[5].

Recent reviews paint a clear picture: Fibromyalgia is not an “either-or,” but a “both-and.” A current overview of therapies from 2000 to 2023 confirms the benefit of combined approaches: Medications such as duloxetine, milnacipran, and pregabalin, as well as anticonvulsants, can alleviate symptoms; simultaneously, cognitive behavioral therapy, structured physical activity including aquatic training, and mindfulness-based programs show measurable improvements – the best efficacy arises in combination ^[6]. Another review from 2020 to 2025 emphasizes the role of central sensitization and neuroinflammation and reports improvements in pain, sensitivity, and sleep through multidisciplinary interventions – from myofascial techniques to resistance training and complementary modalities – with accompanying changes in biomarkers as a biological echo of clinical progress ^[7]. Concurrently, a recent synthesis supports the multifactorial mechanism (altered pain modulation, mitochondrial dysfunction, autonomic imbalance) and the state of diagnostics: The criteria from 2010/2011 and 2016 enhance the assessment, yet objective markers are still absent; omics data and neuroimaging define potential signatures for future, biomarker-driven precision medicine ^[1].

- Prepare for the doctor’s appointment strategically: Note the pain distribution (body map), sleep quality, fatigue, cognitive problems, and triggers. Refer to the current diagnostic criteria (2010/2011, updated in 2016) – this way, you speak the language of the clinic and shorten diagnostic loops [Ref39941626; Ref41821986; Ref41751339; Ref41097025].
- Make symptoms visible: Formulate clear concerns instead of indirect hints. Describe intensity, progression, impairments, and goals. This promotes patient-centered responses and prevents misunderstandings ^[2].
- Educate yourself about your condition: Plan 2–3 learning sprints per week (10 minutes) on pathophysiology, comorbidities, and treatment pathways. Better knowledge enhances self-efficacy and therapy adherence [Ref38242011; Ref41821986].
- Start a dosed exercise program: 3–4 sessions per week, beginning with 10–20 minutes of light aerobic activity (e.g., walking, cycling), gradually supplemented by light strength training (twice a week) and – if available – aquatic training. Goal: pain reduction, better function, increased HRQoL; serious side effects are rare ^[8].
- Integrate CBT purposefully: Classical CBT and exposure CBT reduce avoidance behavior, catastrophizing, and hyper-vigilance – key factors in symptom burden. Choose a program with weekly sessions and homework; the focus is on behavior and thought patterns, not just measuring pain ^[9].
- Optimize your nutrition gradually: Shift to a plant-heavy, Mediterranean profile (vegetables, legumes, whole grains, nuts, fish/seafood, omega-3 sources). The goal is a low Dietary Inflammatory Indexmeasure of dietary inflammation potential, which is associated with less pressure pain sensitivity [Ref31553453; Ref37976478].
- Regularly review new treatment options: Discuss progress in pharmacotherapy (e.g., duloxetine, pregabalin, milnacipran) and complementary approaches such as mindfulness or aquatic training with your team. Multidisciplinary concepts yield the most robust effects [Ref38034135; Ref40582925; Ref41097025].

Research is clearly moving in the direction of precision medicine: Omics signatures and digital phenotyping could soon connect subjective reports with objective biomarkers – and accelerate diagnoses. In the coming years, biomarker-driven, personalized treatment pathways that tailor movement, psychology, and pharmacology are realistic [Ref41751339; Ref41097025].